

ITEM 6. SELECTED FINANCIAL DATA*(In thousands, except per share data)*

We completed the acquisitions of AMRIX® in August 2007, the issued share capital of Zeneus Holdings Limited on December 22, 2005, substantially all assets related to the TRISENOX® (arsenic trioxide) injection business from CTI and CTI Technologies, Inc., a wholly-owned subsidiary of CTI on July 18, 2005, outstanding capital stock of Salmedix, Inc. on June 14, 2005 and the outstanding shares of capital stock of CIMA LABS on August 12, 2004. These acquisitions have been accounted for either as business combinations or asset purchases.

Statement of operations data	Year Ended December 31,				
	2007	2006	2005	2004	2003
Sales	\$ 1,727,299	\$ 1,720,172	\$ 1,156,518	\$ 980,375	\$ 685,250
Other revenues	45,339	43,897	55,374	35,050	29,557
Total revenues	<u>1,772,638</u>	<u>1,764,069</u>	<u>1,211,892</u>	<u>1,015,425</u>	<u>714,807</u>
Settlement reserve	425,000	—	—	—	—
Impairment charges	—	12,417	20,820	30,071	—
Acquired in-process research and development	—	5,000	366,815	185,700	—
Debt exchange expense	—	48,122	—	28,230	—
Write-off of deferred debt issuance costs	—	13,105	27,109	—	—
Income tax expense (benefit)	123,285	93,438	(70,164)	45,629	46,456
Net income (loss)	<u>\$ (191,704)</u>	<u>\$ 144,816</u>	<u>\$ (174,954)</u>	<u>\$ (73,813)</u>	<u>\$ 83,858</u>
Basic income (loss) per common share	<u>\$ (2.88)</u>	<u>\$ 2.39</u>	<u>\$ (3.01)</u>	<u>\$ (1.31)</u>	<u>\$ 1.49</u>
Weighted average number of common shares outstanding	<u>66,597</u>	<u>60,507</u>	<u>58,051</u>	<u>56,489</u>	<u>55,560</u>
Diluted income (loss) per common share	<u>\$ (2.88)</u>	<u>\$ 2.08</u>	<u>\$ (3.01)</u>	<u>\$ (1.31)</u>	<u>\$ 1.42</u>
Weighted average number of common shares outstanding-assuming dilution	<u>66,597</u>	<u>69,672</u>	<u>58,051</u>	<u>56,489</u>	<u>64,076</u>
Balance sheet data	December 31,				
	2007	2006	2005	2004	2003
Cash, cash equivalents and investments	\$ 826,265	\$ 521,724	\$ 484,090	\$ 791,676	\$ 1,155,163
Total assets	3,506,269	3,045,497	2,819,206	2,396,922	2,381,656
Current portion of long-term debt	1,237,169	1,023,312	933,160	5,114	9,637
Long-term debt (excluding current portion)	3,788	224,992	763,097	1,284,410	1,409,417
Accumulated deficit	(624,128)	(425,256)	(570,072)	(395,118)	(321,305)
Stockholders' equity	1,302,067	1,309,460	612,171	830,044	770,370